Glycogen phosphorylase inhibition as a therapeutic target: a review of the recent patent literature

Author： Baker David J   Greenhaff Paul L   Timmons James A  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.16, Iss.4, 2006-04, pp. : 459-466

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glycogen phosphorylase inhibitors: a patent review (2008 - 2012)

By Gaboriaud-Kolar Nicolas   Skaltsounis Alexios-Leandros  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 8, 2013-08 ,pp. : 1017-1032

Informa Healthcare

Access to resources Recommend Favorite

Recent Advances in the Allosteric Inhibition of Glycogen Phosphorylase

By  

Mini Reviews in Medicinal Chemistry, Vol. 10, Iss. 12, 2010-10 ,pp. : 1139-1155

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of Glycogen Phosphorylase in the Context of Type 2 Diabetes, with Focus on Recent Inhibitors Bound at the Active Site

By  

Mini Reviews in Medicinal Chemistry, Vol. 10, Iss. 12, 2010-10 ,pp. : 1102-1126

Bentham Science Publishers

Access to resources Recommend Favorite

BRAF as a therapeutic target: a patent review (2006 – 2012)

By Zambon Alfonso   Niculescu-Duvaz Dan   Niculescu-Duvaz Ion   Marais Richard   Springer Caroline J  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 2, 2013-02 ,pp. : 155-164

Informa Healthcare

Access to resources Recommend Favorite

Inhibitors of PDE4: a review of recent patent literature

By Odingo Joshua O  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 7, 2005-07 ,pp. : 773-787

Informa Healthcare

Access to resources Recommend Favorite